Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Amfetamine extended-release (liquid suspension) - Aytu BioPharma

Next Previous
Search
Drug Profile

Amfetamine extended-release (liquid suspension) - Aytu BioPharma

Alternative Names: Adzenys ER; AMP XR OS; Amphetamine extended-release oral suspension; Amphetamine XR-liquid suspension; Amphetamine XR-suspension - Aytu BioPharma ; Extended release amphetamine liquid suspension - Aytu BioPharma; NT-0201

Latest Information Update: 24 Mar 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Neos Therapeutics
  • Developer Aytu BioPharma
  • Class Amphetamines; Antipsychotics; Behavioural disorder therapies; Small molecules
  • Mechanism of Action Adrenergic receptor agonists; Central nervous system stimulants; Trace amine-associated receptor 1 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Attention-deficit hyperactivity disorder

Most Recent Events

  • 22 Mar 2021 Neos Therapeutics has merged with Aytu BioScience to form Aytu BioPharma
  • 13 Mar 2020 Neos Therapeutics announces intention to launch amfetamine controlled release for Attention deficit hyperactivity disorder in Puerto Rico in the second quarter of 2020
  • 26 Feb 2018 Launched for Attention-deficit hyperactivity disorder (In adolescents, In children, In adults) in USA (PO) - First Global Launch

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top